This medicinal product is for diagnostic use only.
Dotagraf is a contrast agent indicated for enhancement of the contrast in Magnetic Resonance Imaging
(MRI) for a better visualization/delineation in:
Adult and paediatric population (0-18 years)
• MRI of the CNS including lesions of the brain, spine, and surrounding tissues
• Whole body MRI including lesions of the liver, kidneys, pancreas, pelvis, lungs, heart, breast,
and musculoskeletal system.
Adult population
• MR angiography including lesions or stenoses of the non-coronary arteries.
Dotagraf should be used only when diagnostic information is essential and not available with
unenhanced MRI.

Posology
The lowest dose that provides sufficient enhancement for diagnostic purposes should be used. The
dose should be calculated based on the patient’s body weight, and should not exceed the recommended
dose per kilogram of body weight detailed in this section.
Encephalic and spinal MRI
In neurological examinations, the dose can vary from 0.1 to 0.3 mmol/kg BW, corresponding to
0.2 to 0.6 ml/kg BW. After administration of 0.1 mmol/kg BW to patients with brain tumors, the
additional dose of 0.2 mmol/kg BW may improve tumor characterisation and facilitate therapeutic
decision making.
Whole body MRI and Angiography
The recommended dose for intravenous injection is 0.1 mmol/kg BW (i.e. 0.2 ml/kg BW) to provide
diagnostically adequate contrast.
Angiography: In exceptional circumstances (e.g. failure to gain satisfactory images of an extensive
vascular territory) administration of a second consecutive injection of 0.1 mmol/kg BW, equivalent to
0.2 ml/kg BW may be justified. However, if the use of 2 consecutive doses of Dotagraf is anticipated
prior to commencing angiography, use of 0.05 mmol/kg BW, equivalent to 0.1 ml/kg BW for each
dose may be of benefit, depending on the imaging equipment available.
Special populations
Impaired renal function
The adult dose applies to patients with mild to moderate renal impairment (GFR ≥ 30 ml/min/1.73 m2).
Dotagraf should only be used in patients with severe renal impairment (GFR < 30 ml/min/1.73 m2) and
in patients in the perioperative liver transplantation period after careful risk/benefit assessment and if
the diagnostic information is essential and not available with non-contrast enhanced MRI (see
section 4.4). If it is necessary to use Dotagraf, the dose should not exceed 0.1 mmol/kg body weight.
More than one dose should not be used during a scan. Because of the lack of information on repeated
administration, Dotagraf injections should not be repeated unless the interval between injections is at
least 7 days.
Elderly (aged 65 years and above)
No dosage adjustment is considered necessary. Caution should be exercised in elderly patients (see
section 4.4).
Impaired hepatic function
The adult dose applies to these patients. Caution is recommended, especially in the case of
perioperative liver transplantation period (see above impaired renal function).
Paediatric population
MRI of brain and spine / whole-body MRI: the recommended and maximum dose of Dotagraf is
0.1 mmol/kg BW. More than one dose should not be used during a scan.
Due to immature renal function in neonates up to 4 weeks of age and infants up to 1 year of age,
Dotagraf should only be used in these patients after careful consideration at a dose not exceeding
0.1 mmol/kg body weight. More than one dose should not be used during a scan. Because of the lack
of information on repeated administration, Dotagraf injections should not be repeated unless the
interval between injections is at least 7 days.
Dotagraf is not recommended for angiography in children under 18 years of age due to insufficient
data on efficacy and safety in this indication.
Method of administration
The product is indicated for intravenous administration only.

Infusion rate: 3-5 ml/min (higher infusion rates up to 120 ml/min, i.e. 2 ml/sec, may be used for
angiographic procedures)
Optimal imaging: within 45 minutes after injection
Optimal image sequence: T1-weighted
Intravascular administration of contrast media should, if possible, be done with the patient lying
down. After the administration, the patient should be kept under observation for at least half an hour,
since experience shows that the majority of undesirable effects occur within this time.
Prepare a syringe with a needle. Remove the plastic disk. After cleaning the stopper with a pad
soaked in alcohol, puncture the stopper with the needle. Withdraw the quantity of product required
for the examination and inject it intravenously.
For single use only, any unused solution should be discarded.
The solution for injection should be inspected visually prior to use. Only clear solutions free of
visible particles should be used.
Paediatric population
Depending on the amount of Dotagraf to be given to the child, it is preferable to use Dotagraf vials
with a single use syringe of a volume adapted to this amount in order to have a better precision of the
injected volume.
In neonates and infants the required dose should be administered by hand.

Do not use by intrathecal route. Take care to maintain strictly intravenous injection: extravasation
may result in local intolerance reactions, requiring the usual local care.
The usual precaution measures for MRI examination should be taken, such as exclusion of patients
with pacemakers, ferromagnetic vascular clips, infusion pumps, nerve stimulators, cochlear implants,
or suspected intracorporal metallic foreign bodies, particularly in the eye.
Hypersensitivity
• As with other gadolinium containing contrast media, hypersensitivity reactions can occur,
including life-threatening (see section 4.8). Hypersensitivity reactions may be either allergic
(described as anaphylactic reactions when serious) or non allergic. They can be either
immediate (less than 60 minutes), or delayed (up to 7 days). Anaphylactic reactions occur
immediately and can be fatal. They are independent of the dose, can occur after even the first
dose of the product, and are often unpredictable.
• There is always a risk of hypersensitivity regardless of the dose injected.
• Patients who have already experienced a reaction during previous administration of a
gadolinium-containing MRI contrast agent present an increased risk of experiencing another
reaction on subsequent administration of the same product, or possibly other products, and are
therefore considered to be at high risk.
• The injection of gadoteric acid may aggravate symptoms of an existing asthma. In patients with
asthma unbalanced by the treatment, the decision to use gadoteric acid must be made after
careful evaluation of the risk-benefit ratio.
• As known from the use of iodinated contrast media, hypersensitivity reactions can be
aggravated in patients on beta-blockers, and particularly in the presence of bronchial asthma.
These patients may be refractory to standard treatment of hypersensitivity reactions with betaagonists.

• Before any contrast medium is injected, the patient should be questioned for a history of
allergy (e.g. seafood allergy, hay fever, hives), sensitivity to contrast media and bronchial
asthma as the reported incidence of adverse reactions to contrast media is higher in patients
with these conditions and premedication with antihistamines and/or glucocorticoids may be
considered.
• During the examination, supervision by a physician is necessary. If hypersensitivity reactions
occur, administration of the contrast medium must be discontinued immediately and - if
necessary - specific therapy instituted. A venous access should thus be kept during the entire
examination. To permit immediate emergency countermeasures, appropriate drugs (e.g.
epinephrine and antihistamines), an endotracheal tube and a respirator should be ready at hand.
Impaired renal function
Prior to administration of Dotagraf, it is recommended that all patients are screened for renal
dysfunction by obtaining laboratory tests.
There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of some
gadolinium- containing contrast agents in patients with acute or chronic severe renal impairment
(GFR < 30 ml/min/1.73 m2). Patients undergoing liver transplantation are at particular risk since the
incidence of acute renal failure is high in this group. As there is a possibility that NSF may occur with
Dotagraf, it should therefore only be used in patients with severe renal impairment and in patients in
the perioperative liver transplantation period after careful risk/benefit assessment and if the diagnostic
information is essential and not available with non-contrast enhanced MRI.
Haemodialysis shortly after gadoteric acid administration may be useful at removing gadoteric acid
from the body. There is no evidence to support the initiation of haemodialysis for prevention or
treatment of NSF in patients not already undergoing haemodialysis.
Elderly
As the renal clearance of gadoteric acid may be impaired in the elderly, it is particularly important to
screen patients aged 65 years and older for renal dysfunction.
Paediatric population
Neonates and infants
Due to immature renal function in neonates up to 4 weeks of age and infants up to 1 year of age,
Dotagraf should only be used in these patients after careful consideration.
Cardiovascular disease
In patients with severe cardiovascular disease Dotagraf should only be administrated after careful risk
benefit assessment because only limited data are available so far.
CNS disorders
Like with other gadolinium containing contrast agents special precaution is necessary in patients with
a low threshold for seizures. Precautionary measures should be taken, e.g. close monitoring. All
equipment and drugs necessary to counter any convulsions which may occur must be made ready for
use beforehand.

No interactions with other medicinal products have been observed. Formal drug interaction studies
have not been carried out.
Concomitant medications to be taken into account
Beta-blockers, vasoactive substances, angiotensin-converting enzyme inhibitors, angiotensin II
receptor antagonists: these medicinal products decrease the efficacy of the mechanisms of
cardiovascular compensation for blood pressure disorders: the radiologist must be informed before
injection of gadolinium complexes, and resuscitation equipment must be at hand.

Pregnancy
There are no data from the use of gadoteric acid in pregnant women. Animal studies do not indicate
direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). Gadoteric
acid crosses the placenta slowly. Dotagraf should not be used during pregnancy unless the clinical
condition of the woman requires use of gadoteric acid.
Breast-feeding
Gadolinium containing contrast agents are excreted into breast milk in very small amounts (see
section 5.3). At clinical doses, no effects on the infant are anticipated due to the small amount
excreted in milk and poor absorption from the gut. Continuing or discontinuing breast feeding for a
period of 24 hours after administration of Dotagraf, should be at the discretion of the doctor and
lactating mother

No studies on the effects on the ability to drive and use machines have been performed. Ambulant
patients while driving vehicles or operating machinery should take into account that nausea may
incidentally occur

Side effects in association with the use of gadoteric acid are usually mild to moderate in intensity and
transient in nature. Injection site reactions, nausea and headaches are the most frequently observed
reactions.
During clinical trials, nausea, headache, injection site reactions, feeling cold, hypotension,
somnolence, dizziness, feeling hot, burning sensation, rash, asthenia, dysgeusia and hypertension
were the most frequent, uncommonly observed (≥1/1,000 to <1/100) related adverse events.
Since post-marketing, the most commonly reported adverse reactions following administration of
gadoteric acid are nausea, vomiting, pruritus and hypersensitivity reactions.
In hypersensitivity reactions, the reactions most frequently observed are skin reactions, which can be
localized, extended or generalized.
These reactions occur most often immediately (during the injection or within one hour after the start
of injection) or sometimes delayed (one hour to several days after injection), presenting as skin
reactions in this case.
Immediate reactions include one or more effects, which appear simultaneously or sequentially, which
are most often cutaneous, respiratory, gastrointestinal, articular and/or cardiovascular reactions. Each
sign may be a warning sign of a starting shock and leads very rarely to death.
Isolated cases of nephrogenic systemic fibrosis (NSF) have been reported with gadoteric acid, most
of which were in patients co-administered other gadolinium-containing contrast agents (see
section 4.4).
The adverse reactions are listed in the table below by SOC (System Organ Class) and by frequency
with the following guidelines: very common (≥1/10), common (≥1/100 to <1/10), uncommon
(≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be
estimated from the available data). The data presented are from clinical trials involving 2822 patients
when available, or from a pool of observational studies involving 185,500 patients

Adverse reaction in Children
Safety of paediatric patients was considered in clinical trials and postmarketing studies. As compared
to adult, the safety profile of gadoteric acid did not show any specificity in children. Most of
reactions are gastrointestinal symptoms or signs of hypersensitivity.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product.
To report any side effect(s):
The National Pharmacovigilance Centre (NPC).
Fax: +966-11-205-7662
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa

Gadoteric acid can be removed by haemodialysis. However there is no evidence that haemodialysis
is suitable for prevention of nephrogenic systemic fibrosis (NSF).

Pharmacotherapeutic group: paramagnetic contrast media
ATC code: V08CA02 (gadoteric acid).
Dotagraf is a paramagnetic contrast agent for magnetic resonance imaging. The contrast-enhancing
effect is mediated by gadoteric acid which is a ionic gadolinium complex composed out of
Gadolinium oxide and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and
present as meglumine salt.
The paramagnetic effect (relaxivity) is determined from the effect on spin-lattice relaxation time
(T1) about 3.4 mmol-1 · L ·sec-1 and on the spin-spin relaxation time (T2) about 4.27 mmol-1 · L·
sec-1.

After intravenous administration gadoteric acid is quickly distributed in the extracellular fluids. The
distribution volume was approx. 18 l which is approximately equal to the volume of extra-cellular
fluid. Gadoteric acid does not bind to proteins like serum albumin.
Gadoteric acid is eliminated rapidly (89 % after 6 h, 95 % after 24 h) in unchanged form through the
kidneys by glomerular filtration. Excretion via the feces is negligible. No metabolites were detected.
The elimination half life amounts to about 1.6 hours in patients with a normal renal function. In
renally impaired patients, the elimination half life was increased to approximately 5 hours for a
creatinine clearance between 30 and 60 ml/min and approximately 14 hours for a creatinine clearance
between 10 and 30 ml/min.
In animal experiments it has been demonstrated that gadoteric acid can be removed by dialysis

Non-clinical data reveal no special hazard for humans based on conventional studies of safety
pharmacology, repeated dose toxicity, genotoxicity or toxicity to reproduction.
Animal studies have shown negligible (less than 1 % of the administered dose) secretion of gadoteric
acid in maternal milk

Meglumine
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
Water for injections

In the absence of compatibility studies, this medicinal product must not be mixed with other
medicinal products

Store below 30°C .

1 and 10 Type II single-use colourless glass vials of 10 ml and 20 ml (filled to 15 or 20 ml), sealed
with a stopper of bromobutyl rubber and packed in unit carton box.
Not all pack sizes may be marketed

The peel-off tracking label on the vials should be stuck onto the patient record to enable accurate
recording of the gadolinium contrast agent used. The dose used should also be recorded. If electronic
patient records are used, the name of the product, the batch number and the dose should be entered
into the patient record.
Any unused medicinal product or waste material should be disposed of in accordance with local
requirements